KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Taxes (2016 - 2017)

Teva Pharmaceutical Industries filings provide 6 years of Change in Taxes readings, the most recent being $54.0 million for Q1 2017.

  • On a quarterly basis, Change in Taxes fell 76.32% to $54.0 million in Q1 2017 year-over-year; TTM through Mar 2017 was $347.0 million, a 54.22% decrease, with the full-year FY2016 number at $521.0 million, down 17.82% from a year prior.
  • Change in Taxes hit $54.0 million in Q1 2017 for Teva Pharmaceutical Industries, down from $57.0 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $249.0 million in Q4 2015 to a low of -$222.0 million in Q2 2013.
  • Median Change in Taxes over the past 5 years was $104.0 million (2015), compared with a mean of $103.4 million.
  • Biggest five-year swings in Change in Taxes: surged 1233.33% in 2014 and later crashed 77.11% in 2016.
  • Teva Pharmaceutical Industries' Change in Taxes stood at $114.0 million in 2013, then surged by 63.16% to $186.0 million in 2014, then surged by 33.87% to $249.0 million in 2015, then crashed by 77.11% to $57.0 million in 2016, then dropped by 5.26% to $54.0 million in 2017.
  • The last three reported values for Change in Taxes were $54.0 million (Q1 2017), $57.0 million (Q4 2016), and $207.0 million (Q3 2016) per Business Quant data.